AMLXAmylyx Pharmaceuticals, Inc.
What is the market doing?
No clear lean: nothing decisive, though heavily shorted (+12% of shares).
Choppy, but holding above its 200-day average. Oversold (RSI 25). Price is +52% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 8, 2026; selling is often routine (taxes, diversification).
Heavily shorted, settled Sep 15, 2026, more than a week of normal trading to cover, a crowded exit.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How AMLX is trading
Amylyx Pharmaceuticals, Inc. is +111% over the past year while the S&P 500 is +18%: 93 points ahead of the market.
1-year return · S&P 500 +18%
- vs 200-day average
- +52%
vs 200-day average · a clear uptrend
- RSI (14)
- 25
RSI (14) · oversold, sold harder than it has been bought
- Below its 52-week high
- 29%
Below its 52-week high
Details›
- Last close2026-10-09
- $28.14
- 1 monthS&P 500 +2.7%
- −12%
- 1 yearS&P 500 +18%
- +111%
- vs 50-day average$29.84
- −5.7%
- 52-week high
- $39.67
- 52-week low
- $11.38
- Annualised volatility
- 78%
- Insider buying, net, 6 monthsForms 3/4/5 to 2026-10-08
- −$2.9M
| Year | Return |
|---|---|
| 2026 (year to date) | +133% |
| 2025 | +220% |
| 2024 | −74% |
| 2023 | −60% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 4 | 3 of 4 | +7.4% |
| Feb | 5 | 3 of 5 | +8.9% |
| Mar | 5 | 1 of 5 | −32% |
| Apr | 5 | 2 of 5 | −2.0% |
| May | 5 | 1 of 5 | −5.8% |
| Jun | 5 | 4 of 5 | +32% |
| Jul | 5 | 5 of 5 | +19% |
| Aug | 5 | 3 of 5 | +17% |
| Sep | 5 | 3 of 5 | +15% |
| Oct | 5 | 3 of 5 | +16% |
| Nov | 4 | 3 of 4 | +1.1% |
| Dec | 4 | 1 of 4 | −13% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Drug Manufacturers, Specialty & Generic
Ranks #39 of 41 by RyuScore